3-bromo-N-[1-(2,3-dihydro-1-benzofuran-3-yl)-3-methyl-2-oxopyrrolidin-3-yl]benzamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-bromo-N-[1-(2,3-dihydro-1-benzofuran-3-yl)-3-methyl-2-oxopyrrolidin-3-yl]benzamide
• 化学式: C₂₀H₁₉BrN₂O₃
• 分子量: 415.3
• InChiKey: UHISTEZCRUDRKP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1183238A1

  公开（公告）日：2002-03-06
• [EN] METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DE RECEPTEUR DE GLUTAMATE METABOTROPIQUE
  申请人：LILLY CO ELI

  公开号：WO2000069816A1

  公开（公告）日：2000-11-23

  This invention relates to a novel series of compounds which are useful in the treatment or prevention of a physiological disorder associated with an excess of stimulation of the human Group I metabotropic glutamate receptors, especially those designated as mGluR5. This invention also provides methods for the treatment of such disorders, as well as pharmaceutical formulations which employ the novel metabotropic glutamate receptor antagonists to which the present invention relates.